SARS-CoV-2 infection in the COPD population is associated with increased healthcare utilization: An analysis of Cleveland clinic's COVID-19 registry

被引:52
作者
Attaway, Amy A. [1 ]
Zein, Joe [1 ,2 ]
Hatipoglu, Umur S. [1 ]
机构
[1] Cleveland Clin, Resp Inst, 9500 Euclid Ave A-90, Cleveland, OH 44195 USA
[2] Cleveland Clin, Lerner Res Inst, Cleveland, OH 44106 USA
基金
美国国家卫生研究院;
关键词
SARS-CoV-2; COVID-19; COPD; OBSTRUCTIVE PULMONARY-DISEASE; CORTICOSTEROID TREATMENT; PREVALENCE; MORTALITY; COMORBIDITIES; VALIDATION; STRENGTH; IMPACT;
D O I
10.1016/j.eclinm.2020.100515
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We sought to determine whether COPD conferred a higher risk for healthcare utilization in terms of hospitalization and clinical outcomes due to COVID-19. Methods: A cohort study with covariate adjustment using multivariate logistic regression was conducted at the Cleveland Clinic Health System in Ohio and Florida. Symptomatic patients aged 35 years and older who were tested for SARS-CoV-2 between March 8 and May 13, 2020 were included. Findings: 15,586 individuals tested for COVID-19 at the Cleveland Clinic between March 8, 2020 and May 13, 2020 met our inclusion criteria. 12.4% of COPD patients (164/1319) tested positive for COVID-19 compared to 16.6% (2363/14,267) of the non-COPD population. 48.2% (79/164) of COVID-19 positive COPD patients required hospitalization and 45.6% (36/79) required ICU admission. After adjustment for covariates, rates of COVID-19 infection were not significantly different than the non-COPD population (adj OR 0.97; CI: 0.89 -1.05), but COPD patients had increased healthcare utilization as demonstrated by risk for hospitalization (adj OR 1.36; CI: 1.15-1.60), ICU admission (OR 1.20; CI: 1.02-1.40), and need for invasive mechanical ventilation (adj OR 1.49; CI: 1.28-1.73). Unadjusted risk for in-hospital mortality was higher in the COPD population (OR 1.51; CI: 1.14-1.96). After adjusting for covariates however, the risk for in-hospital mortality was not significantly different than the non-COPD population (adj OR 1.08: CI: 0.81-1.42). Interpretation: Our analysis demonstrated that COPD patients with COVID-19 had a higher risk for healthcare utilization, although adjusted in-hospital mortality risk was not different than the non-COPD patients with COVID-19. (C) 2020 The Authors. Published by Elsevier Ltd.
引用
收藏
页数:8
相关论文
共 40 条
[11]   Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease [J].
Horita, Nobuyuki ;
Miyazawa, Naoki ;
Morita, Satoshi ;
Kojima, Ryota ;
Inoue, Miyo ;
Ishigatsubo, Yoshiaki ;
Kaneko, Takeshi .
RESPIRATORY RESEARCH, 2014, 15
[12]   Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. [J].
Hurst, John R. ;
Vestbo, Jorgen ;
Anzueto, Antonio ;
Locantore, Nicholas ;
Muellerova, Hana ;
Tal-Singer, Ruth ;
Miller, Bruce ;
Lomas, David A. ;
Agusti, Alvar ;
MacNee, William ;
Calverley, Peter ;
Rennard, Stephen ;
Wouters, Emiel F. M. ;
Wedzicha, Jadwiga A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (12) :1128-1138
[13]   Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation [J].
Jones, Sarah E. ;
Maddocks, Matthew ;
Kon, Samantha S. C. ;
Canavan, Jane L. ;
Nolan, Claire M. ;
Clark, Amy L. ;
Polkey, Michael I. ;
Man, William D-C .
THORAX, 2015, 70 (03) :213-218
[14]   The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application [J].
Lauer, Stephen A. ;
Grantz, Kyra H. ;
Bi, Qifang ;
Jones, Forrest K. ;
Zheng, Qulu ;
Meredith, Hannah R. ;
Azman, Andrew S. ;
Reich, Nicholas G. ;
Lessler, Justin .
ANNALS OF INTERNAL MEDICINE, 2020, 172 (09) :577-+
[15]   Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients [J].
Lee, N ;
Chan, KCA ;
Hui, DS ;
Ng, EKO ;
Wu, A ;
Chiu, RWK ;
Wong, VWS ;
Chan, PKS ;
Wong, KT ;
Wong, E ;
Cockram, CS ;
Tam, JS ;
Sung, JJY ;
Lo, YD .
JOURNAL OF CLINICAL VIROLOGY, 2004, 31 (04) :304-309
[16]   ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19 [J].
Leung, Janice M. ;
Yang, Chen X. ;
Tam, Anthony ;
Shaipanich, Tawimas ;
Hackett, Tillie-Louise ;
Singhera, Gurpreet K. ;
Dorscheid, Delbert R. ;
Sin, Don D. .
EUROPEAN RESPIRATORY JOURNAL, 2020, 55 (05)
[17]   Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus [J].
Li, WH ;
Moore, MJ ;
Vasilieva, N ;
Sui, JH ;
Wong, SK ;
Berne, MA ;
Somasundaran, M ;
Sullivan, JL ;
Luzuriaga, K ;
Greenough, TC ;
Choe, H ;
Farzan, M .
NATURE, 2003, 426 (6965) :450-454
[18]  
Medina Michelle, 2020, Cleve Clin J Med, DOI 10.3949/ccjm.87a.ccc028
[19]   Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19) [J].
Mehta, Neil ;
Kalra, Ankur ;
Nowacki, Amy S. ;
Anjewierden, Scott ;
Han, Zheyi ;
Bhat, Pavan ;
Carmona-Rubio, Andres E. ;
Jacob, Miriam ;
Procop, Gary W. ;
Harrington, Susan ;
Milinovich, Alex ;
Svensson, Lars G. ;
Jehi, Lara ;
Young, James B. ;
Chung, Mina K. .
JAMA CARDIOLOGY, 2020, 5 (09) :1020-1026
[20]   Extracting and utilizing electronic health data from Epic for research [J].
Milinovich, Alex ;
Kattan, Michael W. .
ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)